| Structural highlights
Function
POLG_POL1M Capsid proteins VP1, VP2, VP3 and VP4 form a closed capsid enclosing the viral positive strand RNA genome. VP4 lies on the inner surface of the protein shell formed by VP1, VP2 and VP3. All the three latter proteins contain a beta-sheet structure called beta-barrel jelly roll. Together they form an icosahedral capsid (T=3) composed of 60 copies of each VP1, VP2, and VP3, with a diameter of approximately 300 Angstroms. VP1 is situated at the 12 fivefold axes, whereas VP2 and VP3 are located at the quasi-sixfold axes. The interaction of five VP1 proteins in the fivefold axes results in a prominent protusion extending to about 25 Angstroms from the capsid shell. The resulting structure appears as a steep plateau encircled by a valley or cleft. This depression also termed canyon is the receptor binding site. The capsid interacts with human PVR at this site to provide virion attachment to target cell. This attachment induces virion internalization predominantly through clathrin- and caveolin-independent endocytosis in Hela cells and through caveolin-mediated endocytosis in brain microvascular endothelial cells. VP4 and VP1 subsequently undergo conformational changes leading to the formation of a pore in the endosomal membrane, thereby delivering the viral genome into the cytoplasm.[1] [2] [3] VP0 precursor is a component of immature procapsids (By similarity).[4] [5] [6] Protein 2A is a cysteine protease that is responsible for the cleavage between the P1 and P2 regions. It cleaves the host translation initiation factor EIF4G1, in order to shut down the capped cellular mRNA transcription.[7] [8] [9] Protein 2B affects membrane integrity and cause an increase in membrane permeability (By similarity).[10] [11] [12] Protein 2C associates with and induces structural rearrangements of intracellular membranes. It displays RNA-binding, nucleotide binding and NTPase activities.[13] [14] [15] Protein 3A, via its hydrophobic domain, serves as membrane anchor. It also inhibits endoplasmic reticulum-to-Golgi transport (By similarity).[16] [17] [18] Protein 3C is a cysteine protease that generates mature viral proteins from the precursor polyprotein. In addition to its proteolytic activity, it binds to viral RNA, and thus influences viral genome replication. RNA and substrate bind co-operatively to the protease (By similarity).[19] [20] [21] RNA-directed RNA polymerase 3D-POL replicates genomic and antigenomic RNA by recognizing replications specific signals (By similarity).[22] [23] [24]
Evolutionary Conservation
Check, as determined by ConSurfDB. You may read the explanation of the method and the full data available from ConSurf.
Publication Abstract from PubMed
BACKGROUND: Picornaviruses, such as the structurally related polioviruses and rhinoviruses, are important human pathogens which have been the target of major drug development efforts. Receptor-mediated uncoating and thermal inactivation of poliovirus and rhinovirus are inhibited by agents that bind to each virus by inserting into a pocket in the beta barrel of the viral capsid protein, VP1. This pocket, which is normally empty in human rhinovirus-14 (HRV14), is occupied by an unknown natural ligand in poliovirus. Structural studies of HRV14-drug complexes have shown that drug binding causes large, localized changes in the conformation of VP1. RESULTS: We report the crystal structures of six complexes between poliovirus and capsid-binding, antiviral drugs, including complexes of four different drugs with the Sabin vaccine strain of type 3 poliovirus, and complexes of one of these drugs with two other poliovirus strains that contain sequence differences in the drug-binding site. In each complex, the changes in capsid structure associated with drug binding are limited to minor adjustments in the conformations of a few side chains lining the binding site. CONCLUSIONS: The minor structural changes caused by drug binding suggest a model of drug action in which it is the conformational changes prevented by the bound drug, rather than obvious conformational changes induced by drug binding, which exert the biological effect. Our results, along with additional structures of rhinovirus-drug complexes, suggest possible improvements in drug design, and provide important clues about the nature of the conformational changes that are involved in the uncoating process.
Structures of poliovirus complexes with anti-viral drugs: implications for viral stability and drug design.,Grant RA, Hiremath CN, Filman DJ, Syed R, Andries K, Hogle JM Curr Biol. 1994 Sep 1;4(9):784-97. PMID:7820548[25]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
See Also
References
- ↑ Ventoso I, MacMillan SE, Hershey JW, Carrasco L. Poliovirus 2A proteinase cleaves directly the eIF-4G subunit of eIF-4F complex. FEBS Lett. 1998 Sep 11;435(1):79-83. PMID:9755863
- ↑ Bubeck D, Filman DJ, Cheng N, Steven AC, Hogle JM, Belnap DM. The structure of the poliovirus 135S cell entry intermediate at 10-angstrom resolution reveals the location of an externalized polypeptide that binds to membranes. J Virol. 2005 Jun;79(12):7745-55. PMID:15919927 doi:79/12/7745
- ↑ Bergelson JM. New (fluorescent) light on poliovirus entry. Trends Microbiol. 2008 Feb;16(2):44-7. doi: 10.1016/j.tim.2007.12.004. Epub 2008 , Jan 10. PMID:18191571 doi:10.1016/j.tim.2007.12.004
- ↑ Ventoso I, MacMillan SE, Hershey JW, Carrasco L. Poliovirus 2A proteinase cleaves directly the eIF-4G subunit of eIF-4F complex. FEBS Lett. 1998 Sep 11;435(1):79-83. PMID:9755863
- ↑ Bubeck D, Filman DJ, Cheng N, Steven AC, Hogle JM, Belnap DM. The structure of the poliovirus 135S cell entry intermediate at 10-angstrom resolution reveals the location of an externalized polypeptide that binds to membranes. J Virol. 2005 Jun;79(12):7745-55. PMID:15919927 doi:79/12/7745
- ↑ Bergelson JM. New (fluorescent) light on poliovirus entry. Trends Microbiol. 2008 Feb;16(2):44-7. doi: 10.1016/j.tim.2007.12.004. Epub 2008 , Jan 10. PMID:18191571 doi:10.1016/j.tim.2007.12.004
- ↑ Ventoso I, MacMillan SE, Hershey JW, Carrasco L. Poliovirus 2A proteinase cleaves directly the eIF-4G subunit of eIF-4F complex. FEBS Lett. 1998 Sep 11;435(1):79-83. PMID:9755863
- ↑ Bubeck D, Filman DJ, Cheng N, Steven AC, Hogle JM, Belnap DM. The structure of the poliovirus 135S cell entry intermediate at 10-angstrom resolution reveals the location of an externalized polypeptide that binds to membranes. J Virol. 2005 Jun;79(12):7745-55. PMID:15919927 doi:79/12/7745
- ↑ Bergelson JM. New (fluorescent) light on poliovirus entry. Trends Microbiol. 2008 Feb;16(2):44-7. doi: 10.1016/j.tim.2007.12.004. Epub 2008 , Jan 10. PMID:18191571 doi:10.1016/j.tim.2007.12.004
- ↑ Ventoso I, MacMillan SE, Hershey JW, Carrasco L. Poliovirus 2A proteinase cleaves directly the eIF-4G subunit of eIF-4F complex. FEBS Lett. 1998 Sep 11;435(1):79-83. PMID:9755863
- ↑ Bubeck D, Filman DJ, Cheng N, Steven AC, Hogle JM, Belnap DM. The structure of the poliovirus 135S cell entry intermediate at 10-angstrom resolution reveals the location of an externalized polypeptide that binds to membranes. J Virol. 2005 Jun;79(12):7745-55. PMID:15919927 doi:79/12/7745
- ↑ Bergelson JM. New (fluorescent) light on poliovirus entry. Trends Microbiol. 2008 Feb;16(2):44-7. doi: 10.1016/j.tim.2007.12.004. Epub 2008 , Jan 10. PMID:18191571 doi:10.1016/j.tim.2007.12.004
- ↑ Ventoso I, MacMillan SE, Hershey JW, Carrasco L. Poliovirus 2A proteinase cleaves directly the eIF-4G subunit of eIF-4F complex. FEBS Lett. 1998 Sep 11;435(1):79-83. PMID:9755863
- ↑ Bubeck D, Filman DJ, Cheng N, Steven AC, Hogle JM, Belnap DM. The structure of the poliovirus 135S cell entry intermediate at 10-angstrom resolution reveals the location of an externalized polypeptide that binds to membranes. J Virol. 2005 Jun;79(12):7745-55. PMID:15919927 doi:79/12/7745
- ↑ Bergelson JM. New (fluorescent) light on poliovirus entry. Trends Microbiol. 2008 Feb;16(2):44-7. doi: 10.1016/j.tim.2007.12.004. Epub 2008 , Jan 10. PMID:18191571 doi:10.1016/j.tim.2007.12.004
- ↑ Ventoso I, MacMillan SE, Hershey JW, Carrasco L. Poliovirus 2A proteinase cleaves directly the eIF-4G subunit of eIF-4F complex. FEBS Lett. 1998 Sep 11;435(1):79-83. PMID:9755863
- ↑ Bubeck D, Filman DJ, Cheng N, Steven AC, Hogle JM, Belnap DM. The structure of the poliovirus 135S cell entry intermediate at 10-angstrom resolution reveals the location of an externalized polypeptide that binds to membranes. J Virol. 2005 Jun;79(12):7745-55. PMID:15919927 doi:79/12/7745
- ↑ Bergelson JM. New (fluorescent) light on poliovirus entry. Trends Microbiol. 2008 Feb;16(2):44-7. doi: 10.1016/j.tim.2007.12.004. Epub 2008 , Jan 10. PMID:18191571 doi:10.1016/j.tim.2007.12.004
- ↑ Ventoso I, MacMillan SE, Hershey JW, Carrasco L. Poliovirus 2A proteinase cleaves directly the eIF-4G subunit of eIF-4F complex. FEBS Lett. 1998 Sep 11;435(1):79-83. PMID:9755863
- ↑ Bubeck D, Filman DJ, Cheng N, Steven AC, Hogle JM, Belnap DM. The structure of the poliovirus 135S cell entry intermediate at 10-angstrom resolution reveals the location of an externalized polypeptide that binds to membranes. J Virol. 2005 Jun;79(12):7745-55. PMID:15919927 doi:79/12/7745
- ↑ Bergelson JM. New (fluorescent) light on poliovirus entry. Trends Microbiol. 2008 Feb;16(2):44-7. doi: 10.1016/j.tim.2007.12.004. Epub 2008 , Jan 10. PMID:18191571 doi:10.1016/j.tim.2007.12.004
- ↑ Ventoso I, MacMillan SE, Hershey JW, Carrasco L. Poliovirus 2A proteinase cleaves directly the eIF-4G subunit of eIF-4F complex. FEBS Lett. 1998 Sep 11;435(1):79-83. PMID:9755863
- ↑ Bubeck D, Filman DJ, Cheng N, Steven AC, Hogle JM, Belnap DM. The structure of the poliovirus 135S cell entry intermediate at 10-angstrom resolution reveals the location of an externalized polypeptide that binds to membranes. J Virol. 2005 Jun;79(12):7745-55. PMID:15919927 doi:79/12/7745
- ↑ Bergelson JM. New (fluorescent) light on poliovirus entry. Trends Microbiol. 2008 Feb;16(2):44-7. doi: 10.1016/j.tim.2007.12.004. Epub 2008 , Jan 10. PMID:18191571 doi:10.1016/j.tim.2007.12.004
- ↑ Grant RA, Hiremath CN, Filman DJ, Syed R, Andries K, Hogle JM. Structures of poliovirus complexes with anti-viral drugs: implications for viral stability and drug design. Curr Biol. 1994 Sep 1;4(9):784-97. PMID:7820548
|
